Cancer, Inflammasomes, and Adjuvanticity

摘要: Cancer progression is associated with chronic inflammation and the dampening of antitumor immune responses. Although proinflammatory cytokines such as interleukin-1β (IL-1β) have been proposed to be involved in initial development cancer, there emerging evidence that these molecules can also act potent adjuvants T-cell-mediated The inflammasomes characterized multimeric complexes leading release IL-1β, IL-18, IL-33 after detection danger signals released from stressed or dying cells. Strikingly, activation NLRP3 inflammasome was recently shown instrumental initiation an anticancer response required for success chemotherapy. In this chapter, I review current knowledge on links between cancers, a focus role therapies.